Advanced regenerative medicine company Plcoskin announced that it has secured an additional $2 million investment from Chinese venture capital firm Highlight Capital. The investment was finalized on December 9 in Shanghai during a memorandum of understanding (MOU) signing ceremony attended by Seoul City’s economic affairs commissioner and Highlight Capital. With this latest funding, Plcoskin’s Series C round totals $9.9 million. The company plans to use this investment as a springboard to accelerate its entry into the Chinese market through close collaboration with a leading local investor.
Founded in 2014, Highlight Capital is a global biotech and healthcare-focused investment firm managing approximately $3.8 billion in assets under management (AUM). The firm has invested in more than 150 biotech and healthcare companies worldwide and has previously backed Korean firms such as Meditip and Cellark Bio. Industry observers note that this investment goes beyond financial backing, providing Plcoskin with strategic access to Highlight Capital’s extensive China network and sector expertise.
During the event, an additional MOU was signed between the Seoul Metropolitan Government and Highlight Capital. Under the agreement, Highlight Capital plans to invest a total of $500 million in Seoul-based biotech and healthcare companies over the next five years and to establish a Seoul branch office within the Seoul International Financial Office.
At the ceremony, Plcoskin showcased its core technology—3D printing-based tissue regeneration scaffold technology—drawing strong attention from attendees. The company also outlined its China and global market expansion strategies, presenting a clear roadmap for future growth.
The newly raised funds will be used to secure clinical data required for medical device regulatory approval in China, as well as to respond to regulatory review processes. Plcoskin is pursuing a phased market entry strategy in China, leveraging product approvals and technical data already obtained in Korea.
A company official stated, “This investment from Highlight Capital is a key foothold for entering the Chinese market. The total $9.9 million raised in Series C will be used not only for Chinese regulatory approvals, but also for the development of new biostimulator products and broader global expansion strategies.” The official added, “Through this, we aim to become a global leader in regenerative medical devices, not only in Asia but worldwide.”
Plcoskin is a Korean biohealthcare company with proprietary technologies in skin regeneration, wound healing, and tissue engineering. In its Series A and B rounds, the company attracted investments from major domestic institutional investors based on its product competitiveness and successful supply track record with leading hospitals, establishing a stable growth trajectory.
This investment from Highlight Capital marks Plcoskin’s first funding from a global venture capital firm, signaling international recognition of its technology and growth potential. Going forward, Plcoskin plans to pursue regulatory approvals in China in parallel with entry into major global markets, including the U.S. FDA, as it accelerates the expansion of its global supply network.
Plcoskin CEO Baek Woo-yeol said, “This investment agreement is not merely a capital raise, but a strategic partnership that allows us to leverage local Chinese networks and expertise. We will also deepen cooperation with the Seoul Metropolitan Government to present a model for overseas expansion of K-bio companies.” He added, “Through this, we aim to grow beyond Asia and emerge as a global leader in regenerative medical devices.”
